Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B

Summary

To investigate the safety and efficacy of tenofovir alafenamide (orally 25 mg per day) treated in inactive chronic hepatitis B virus (HBV)-infected pregnant women with high viral load from the late pregnancy until the delivery date or postpartum 1 month.

Timeline

Start

2021-04-26

Primary completion

2022-12-31

Completion

2022-12-31

Publications

• Zeng QL, Zhou YH, Dong XP, Zhang JY, Li GM, Xu JH, Chen ZM, Song N, Zhang HX, Chen RY, Lv XY, Huang S, Li WZ, Pan YJ, Feng YH, Li ZQ, Zhang GF, Lin WB, Zhang GQ, Li GT, Li W, Zeng YL, Zhang DW, Cui GL, Lv J, Liu YM, Liang HX, Sun CY, Wang FS, Yu ZJ. Expected 8-Week Prenatal vs 12-Week Perinatal Tenofovir Alafenamide Prophylaxis to Prevent Mother-to-Child Transmission of Hepatitis B Virus: A Multicenter, Prospective, Open-Label, Randomized Controlled Trial. Am J Gastroenterol. 2025 May 1;120(5):1045-1056. doi: 10.14309/ajg.0000000000003122. Epub 2024 Oct 9.

Drugs

Indications